
Please try another search
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Name | Age | Since | Title |
---|---|---|---|
Young-Jin Kim | 68 | 2019 | Director |
Robert B. Bhisitkul | - | - | Member of the Scientific Advisory Board |
Wladimir Hogenhuis | 59 | 2021 | Independent Director |
Jerrold M. Olefsky | - | 2014 | Member of the Scientific Advisory Board |
Philippe Fauchet | 67 | 2020 | Independent Director |
Quan Dong Nguyen | - | 2021 | Member of the Scientific Advisory Board |
Adrian Vella | - | 2021 | Member of the Scientific Advisory Board |
Nerissa C. Kreher | 51 | 2021 | Independent Director |
Nevan Charles Elam | 57 | 2013 | Founder, CEO, Principal Financial Officer & Acting Chairman of the Board |
So-Hyun Kwon | - | - | Board Observer |
Scott Morenstein | 48 | - | Board Observer |
Erik Harris | 50 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review